Streetbeat News

Analyst Ratings

PFE

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $45 price target.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:25 pm

NVO

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Novo Nordisk (NYSE:NVO) and maintained a $160 price target.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:23 pm

NBIX

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $155.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:21 pm

BLDR

GRBK

MHO

TOL

Homebuilder stocks, including Builders First Source, are rising due to expected Fed rate cuts, declining mortgage rates, and Kamala Harris's homeownership plan. Builders First Source received an upgraded rating from Truist Securities, boosting its stock price.

Portfolio Pulse from Michael Juliano

September 16, 2024 | 4:19 pm

MRNS

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Marinus Pharma (NASDAQ:MRNS) and maintained a $13 price target.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:19 pm

MRK

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Merck & Co (NYSE:MRK) and maintained a price target of $155.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:17 pm

XOM

Morgan Stanley has maintained its Overweight rating on Exxon Mobil but has slightly lowered the price target from $145 to $142.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:16 pm

EOG

Morgan Stanley analyst Devin McDermott maintains an Equal-Weight rating on EOG Resources but lowers the price target from $134 to $132.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:14 pm

FANG

Morgan Stanley analyst Devin McDermott has maintained an Overweight rating on Diamondback Energy and raised the price target from $185 to $198.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:12 pm

MREO

Cantor Fitzgerald has reiterated its Overweight rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:10 pm